Christine Smith
About Christine Smith
Christine Smith is a Pre-Clinical Research and Development Scientist II at Noveome Biotherapeutics, Inc., with a strong academic background in Biochemistry and Biotechnology. Her research focuses on BRAF kinase activity and its implications for cancer treatment.
Work at Noveome Biotherapeutics
Christine Smith has been employed at Noveome Biotherapeutics, Inc. since 2017, where she holds the position of Pre-Clinical Research and Development Scientist II. In this role, she focuses on research that enhances the understanding of BRAF kinase activity regulation. This research is essential for the development of next-generation BRAF inhibitors, which are significant in cancer treatment. Her work contributes to advancing therapeutic strategies in the field of oncology.
Education and Expertise
Christine Smith earned her Bachelor of Science in Biochemistry and Biotechnology from Albright College, where she studied from 2009 to 2013. She achieved a GPA of 3.857/4.0 during her Master's degree studies in Biochemistry at the University of the Sciences in Philadelphia from 2014 to 2016. Her academic background provides a strong foundation in biochemical research, particularly in the areas of signaling pathways and molecular mechanisms.
Background
Christine Smith completed her high school education at Mount Carmel Area High School, graduating with a 4.0 GPA from 2005 to 2009. Following her undergraduate studies, she worked as a Laboratory Assistant at Albright College from 2010 to 2013 and later served as a Laboratory Instructor at the University of the Sciences in Philadelphia from 2014 to 2016. These roles provided her with practical experience in laboratory settings and teaching, enhancing her skills in scientific research and education.
Research Contributions
Christine Smith's research includes a thesis that proposes a novel strategy for regulating MAPK signaling, which has potential implications for cancer treatment strategies. Additionally, she conducted an in vitro study on the molecular mechanisms of wild type full-length BRAF, focusing on key processes such as phosphorylation, dimerization, and the effects of ATP-competitive inhibitors. Her work aims to deepen the understanding of cancer biology and improve therapeutic approaches.